The Furin-COVID-19 Connection Continues but Key Aspects are Missing From the Discussion

More validation is emerging for the furin protease (“furin”) hypothesis I posited in this blog: The Furin Protease Connection: From SARS CoV-2 and Anthrax, to Diabetes and Hypertension and that is now available as a pre-print publication here. Considering furin protease inhibitors Scientists are validating furin inhibition as a possible pathway to addressing COVID. And in this Medical News Today…

Can Unconventional Immunomodulatory Agents Help Alleviate COVID-19 Symptoms and Severity?

ABSTRACT Severe acute respiratory syndrome coronavirus 2 (SARS coronavirus 2, or SARS-CoV-2) is the cause of the respiratory infection known as COVID-19. From an immunopathological standpoint, coronaviruses such as SARS-CoV-2 induce increased levels of a variety of T-helper 1 (Th1) and inflammatory cytokines and chemokines, including interleukin-1 (IL-1), IL-6, CCL2 protein, and CXCL10 protein. In…

SARS

A few additional treatment possibilities in COVID19 (SARS Cov-2) addressing furin-like cleavage and pyroptosis (caspacin-1 activation of inflammasome NLRP3)

The cytokine storm seen in SARS Cov1 and Cov2 might be due to chronic pyroptosis activation. However, known activators of NLRP3 in SARS-CoV differ from CoV2.  While SARS Cov1 and COVID19 are genetically very similar, the extraordinarily high rate of infectivity of COVID19 is unique. Prepublication research suggests the cause might be a unique furin-like cleavage site on the spike protein of Cov2 that was absent in Cov1.